23 assets in Langerhans Cell Histiocytosis

Therapeutic assets addressing Langerhans Cell Histiocytosis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Busulfanum Langerhans Cell Histiocytosis	M.D. Anderson Cancer Center	P2	B (57)
Cyclophosphamide Langerhans Cell Histiocytosis	M.D. Anderson Cancer Center	P2	B (57)
Fludarabine Langerhans Cell Histiocytosis	M.D. Anderson Cancer Center	P2	B (57)
Melphalan Langerhans Cell Histiocytosis	M.D. Anderson Cancer Center	P2	B (57)
Olaparib Langerhans Cell Histiocytosis	National Cancer Institute (NCI)	P2	B (57)
Palbociclib Langerhans Cell Histiocytosis	National Cancer Institute (NCI)	P2	B (57)
PI3K/MTOR INHIBITOR LY3023414 Langerhans Cell Histiocytosis	National Cancer Institute (NCI)	P2	B (57)
Tazemetostat Langerhans Cell Histiocytosis	National Cancer Institute (NCI)	P2	B (57)
Dabrafenib Langerhans Cell Histiocytosis	Cancer Research UK	P2/3	B (56)
Trametinib Langerhans Cell Histiocytosis	Cancer Research UK	P2/3	B (56)
Vemurafenib Langerhans Cell Histiocytosis	National Cancer Institute (NCI)	P2	CCC (55)
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- Langerhans Cell Histiocytosis	National Cancer Institute (NCI)	P2	CCC (53)
Ensartinib Langerhans Cell Histiocytosis	National Cancer Institute (NCI)	P2	CCC (53)
hlx208 Langerhans Cell Histiocytosis	Shanghai Henlius Biotech	P2	CCC (53)
Ivosidenib Langerhans Cell Histiocytosis	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Langerhans Cell Histiocytosis	National Cancer Institute (NCI)	P2	CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Langerhans Cell Histiocytosis	National Cancer Institute (NCI)	P2	CCC (53)
Selpercatinib Langerhans Cell Histiocytosis	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Langerhans Cell Histiocytosis	National Cancer Institute (NCI)	P2	CCC (53)
Ulixertinib Langerhans Cell Histiocytosis	National Cancer Institute (NCI)	P2	CCC (53)
q702 Langerhans Cell Histiocytosis	Mayo Clinic	P1	CC (43)
Alemtuzumab Langerhans Cell Histiocytosis	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Mesna Langerhans Cell Histiocytosis	Masonic Cancer Center, University of Minnesota	N/A	D (30)